Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Jill Wechsler

Washington Editor

Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on government policies and a wide range of topics for business and consumer publications.

Articles
Ebola Crisis Challenges Pharma R&D
October 1, 2014

Companies gain support—and pressure—to deliver new treatments for spreading outbreak.

"Sunshine" Goes Live — Despite Incomplete Information
October 1, 2014

The federal Open Payments program has gone live, but biopharma companies continue to be concerned about the lack of context. Jill Wechsler reports.

Pharma Battles Hospitals Over Discount Pricing Program
September 3, 2014

Continued growth in a program that provides low-cost drugs to safety-net hospitals has sparked "trench warfare" over which medicines and providers are eligible for the discounts, writes Jill Wechsler.

Pharma Battles Hospitals Over 340B Pricing
September 1, 2014

Expansion of drug discount program ignites lawsuits, policy disputes.

Social Media Struggles Continue
August 1, 2014

Tweeting limited, corrections okay, says FDA, as industry, regulators wrestle with the digital world. Our Washington Correspondent Jill Wechsler reports.

Pre-emption and States' Rights
July 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

What Price Innovation?
June 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Compassionate Use Requests Complicate Drug Development
June 1, 2014

Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.

Reimbursement Limits Threaten Drug Access
May 22, 2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

ADVERTISEMENT

Click here